WO2003086456A3 - Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer - Google Patents

Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer Download PDF

Info

Publication number
WO2003086456A3
WO2003086456A3 PCT/CA2003/000500 CA0300500W WO03086456A3 WO 2003086456 A3 WO2003086456 A3 WO 2003086456A3 CA 0300500 W CA0300500 W CA 0300500W WO 03086456 A3 WO03086456 A3 WO 03086456A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
antibodies
therapeutic
monoclonal antibody
diagnostic uses
Prior art date
Application number
PCT/CA2003/000500
Other languages
French (fr)
Other versions
WO2003086456A2 (en
Inventor
David Young
Xiaobo Duan
Timothy C Groves
Original Assignee
Arius Res Inc
David Young
Xiaobo Duan
Timothy C Groves
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arius Res Inc, David Young, Xiaobo Duan, Timothy C Groves filed Critical Arius Res Inc
Priority to AU2003227148A priority Critical patent/AU2003227148A1/en
Publication of WO2003086456A2 publication Critical patent/WO2003086456A2/en
Publication of WO2003086456A3 publication Critical patent/WO2003086456A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening and characterizing the target antigen thereof. The invention further relates to the process by which the antibodies are made and to their methods of use. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and their metastases. The anti-cancer antibodies can be combined with a variety of anti-neoplastic agents, e.g. Cisplatin, to derive a synergistic effect with regard to reduction in tumour growth kinetics and metastasis.
PCT/CA2003/000500 2002-04-05 2003-04-07 Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer WO2003086456A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003227148A AU2003227148A1 (en) 2002-04-05 2003-04-07 Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37065902P 2002-04-05 2002-04-05
US60/370,659 2002-04-05

Publications (2)

Publication Number Publication Date
WO2003086456A2 WO2003086456A2 (en) 2003-10-23
WO2003086456A3 true WO2003086456A3 (en) 2003-12-04

Family

ID=29250562

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/000500 WO2003086456A2 (en) 2002-04-05 2003-04-07 Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer

Country Status (2)

Country Link
AU (1) AU2003227148A1 (en)
WO (1) WO2003086456A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7009040B2 (en) * 2003-01-21 2006-03-07 Arius Research, Inc. Cancerous disease modifying antibodies
US7431923B2 (en) 2005-01-03 2008-10-07 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7534429B2 (en) 2000-11-29 2009-05-19 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7442777B2 (en) 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7361342B2 (en) 2003-01-21 2008-04-22 Arius Research Inc. Cancerous disease modifying antibodies
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US7468254B2 (en) 2003-01-21 2008-12-23 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US7399835B2 (en) * 2004-02-26 2008-07-15 Arius Research Inc. Cancerous disease modifying antibodies
US7456259B2 (en) * 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7452978B2 (en) * 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7452979B2 (en) * 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7494648B2 (en) * 2005-08-02 2009-02-24 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US7411046B2 (en) * 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US7456258B2 (en) * 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031728A1 (en) * 1994-05-17 1995-11-23 Beki Ab Method of detecting cancer involving fragments of cytokeratin 18 and corresponding antibodies
US6180357B1 (en) * 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
WO2003057168A2 (en) * 2002-01-03 2003-07-17 The Scripps Research Institute Cancer-associated epitope

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031728A1 (en) * 1994-05-17 1995-11-23 Beki Ab Method of detecting cancer involving fragments of cytokeratin 18 and corresponding antibodies
US6180357B1 (en) * 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
WO2003057168A2 (en) * 2002-01-03 2003-07-17 The Scripps Research Institute Cancer-associated epitope

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ETO HIROSHI ET AL: "Mapping and regulation of the tumor-associated epitope recognized by monoclonal antibody RS-11.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 35, 1 September 2000 (2000-09-01), pages 27075 - 27083, XP002254882, ISSN: 0021-9258 *
SASAKI M ET AL: "Immunoperoxidase staining for cytokeratins 8 and 18 is very sensitive for detection of occult node metastasis of colorectal cancer: A comparison with genetic analysis of K-ras.", HISTOPATHOLOGY (OXFORD), vol. 32, no. 3, March 1998 (1998-03-01), pages 199 - 208, XP002254883, ISSN: 0309-0167 *

Also Published As

Publication number Publication date
WO2003086456A2 (en) 2003-10-23
AU2003227148A1 (en) 2003-10-27
AU2003227148A8 (en) 2003-10-27

Similar Documents

Publication Publication Date Title
WO2003086456A3 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
SG170728A1 (en) Anti-tumor cell antigen antibody therapeutics
DK1718737T3 (en) Cancerous disease-modifying antibodies
RU2011116112A (en) BSPECIFIC ANTI-EGFR / ANTI-IGF-1R ANTIBODIES
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
EP1996716A4 (en) Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
WO2019204462A3 (en) Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
MX2008008185A (en) De-n-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy.
ZA202008095B (en) Humanized antibodies against psma
PH12020551187A1 (en) Bispecific antigen-binding molecules and methods of use
JP2020533965A5 (en)
DK1613656T3 (en) Cancer disease-modifying antibodies
WO2004065422A3 (en) Cancerous disease modifying antibodies
MX2009001015A (en) Cancerous disease modifying antibodies.
CN107854490A (en) A kind of T cell and its application through modification
WO2002072008A3 (en) Method for treating cancer using a33 specific antibodies and chemotherapeutic agents
WO2005012361A3 (en) Antibodies raised against colon carcinomas
WO2010004438A3 (en) Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
WO2005010153A3 (en) Antibodies and uses thereof
MX2009009919A (en) Cancer disease modifying antibody 010207-01 produced by hybridoma cell line ar51a630.3.
EP1929034A4 (en) Cancerous disease modifying antibodies
NO20091459L (en) Cancerous disease-modifying antibodies
MX2009011667A (en) Cancerous disease modifying antibodies.
MX2009001292A (en) Cancerous disease modifying antibodies.
AR071846A1 (en) CANCEROSE DISEASE MODIFYING ANTIBODIES (CDMAB)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP